Diabetes is a serious epidemic in the United States, as well as other developed and developing countries. As a prevalent, chronic disease affecting around 10% of the adult US population diabetes is a serious public health issue. It has found to be related to numerous adverse outcomes, such as cardiovascular disease, kidney diseases, impaired vision, and increased hospitalizations. In 2017, the costs associated with diabetes was estimated to be $327B.
For the past several years, NIH awards for diabetes-related R&D was between $1B and $1.1B. Funding in 2020 is expected to be close to $1.2B. The majority of funding for diabetes R&D is through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
This webinar will address various funding mechanisms available for diabetes R&D.